# SUPERNUS PHARMACEUTICALS, INC. (SUPN) FY2026 Q2 Balance Sheet

- Company: SUPERNUS PHARMACEUTICALS, INC. (SUPN)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-03, accession number 0001356576-26-000037
- Page: https://plicit.ai/financials/supn/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/supn-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 1,428,109,000 US dollars
- **Current assets**: 723,496,000 US dollars
- **Non-current assets**: 704,613,000 US dollars
- **Liabilities**: 396,883,000 US dollars
- **Current liabilities**: 347,378,000 US dollars
- **Non-current liabilities**: 49,505,000 US dollars
- **Equity**: 1,031,226,000 US dollars
- **Accounts receivable, net**: 211,656,000 US dollars
- **Marketable securities**: 192,114,000 US dollars
- **Cash and cash equivalents**: 179,953,000 US dollars
- **Inventories, net**: 83,924,000 US dollars
- **Prepaid expenses and other current assets**: 55,849,000 US dollars
- **Intangible assets, net**: 469,459,000 US dollars
- **Goodwill**: 119,431,000 US dollars
- **Other assets**: 55,015,000 US dollars
- **Deferred income tax assets, net**: 49,061,000 US dollars
- **Property and equipment, net**: 10,197,000 US dollars
- **Restricted cash**: 1,450,000 US dollars
- **Accrued product returns and rebates**: 198,844,000 US dollars
- **Accounts payable and accrued liabilities**: 108,458,000 US dollars
- **Other current liabilities**: 40,076,000 US dollars
- **Contingent consideration, current portion**: 0 US dollars
- **Operating lease liabilities, long-term**: 29,427,000 US dollars
- **Other liabilities**: 19,872,000 US dollars
- **Contingent consideration, long-term**: 206,000 US dollars
- **Additional paid-in capital**: 574,094,000 US dollars
- **Retained earnings**: 457,212,000 US dollars
- **Common stock, $0.001 par value; 130,000,000 shares authorized; 58,164,352 and 57,457,462 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively**: 58,000 US dollars
- **Accumulated other comprehensive loss, net of tax**: negative 138,000 US dollars
- **Gross equity (calculated)**: 1,031,364,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.